Public Citizen says the HHS Inspector General should probe FDA collaboration with Biogen to salvage the Alzheimers drug aducanumab.
Stakeholders suggest revisions to an FDA draft guidance on pharmacokinetics in patients with impaired renal function.
FDA expands its partnership with Palantir Technologies through a new $44.4 million three-year contract.
Federal Register notice: FDA releases a final guidance entitled Best Practices in Developing Proprietary Names for Human Prescription Drug Products.
Federal Register notice: FDA makes available a draft guidance entitled Best Practices in Developing Proprietary Names for Human Nonprescription Drug P...
FDA warns Natures Boost that it is marketing misbranded unapproved new drugs.
FDA warns Valentus, Inc., that it is taking orders for misbranded unapproved new drugs.
FDA posts a final guidance on Requesting FDA Feedback on Combination Products.